Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583879 | 1.00 | MAPT (0.57) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27874810 | 1.00 | MAPT (0.57) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722247 | 0.86 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27975925 | 0.86 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722208 | 0.86 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL25381943 | 0.86 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27548463 | 0.86 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722248 | 0.84 | MAPT (0.58) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722209 | 0.84 | MAPT (0.58) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL9635609 | 0.84 | MAPT (0.58) | MAPTMAPK1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-118355117-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-12037355-B2 | Triterpene saponin analogues | ADJUVANCE TECHNOLOGIES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12030980-B2 | Reprocessable compositions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-111936136-B | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113710660-B | DOT1L degradation agent and application thereof | 达纳-法伯癌症研究公司 | 2024-07-02 | — | — | CN | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-5872299-A | Method of preparing intermediates for retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5831117-A | ACID SALTS | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0855388-A2 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998029401-A1 | AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT | G.D. SEARLE & CO. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | MAPT 506/4885MAPK1 1159/4885KMT2A 4824/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | MAPT 1864/4885MAPK1 144/4885KMT2A 1338/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885MAPK1 4173/4885KMT2A 4008/4885 |
| US-12037355-B2 | Triterpene saponin analogues | LSS, NFATC1, PGGT1B | MAPT 4290/4885MAPK1 2009/4885KMT2A 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.